Side-by-side · Research reference
TesofensinevsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3Draft10/40 cited
BHuman-MechanisticDraft12/40 cited
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
Tesofensine
Thymalin
Primary target
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
—
—
Origin
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
Tesofensine
Thymalin
Frequency
Once daily, morning
Once daily during cycle
Lower / starter dose
0.125 mg / day
2.5 mg / day
Duration
24 weeks per studied cycle
5–10 day cycles, 1–2× per year
Form
Oral capsule
—
Timing
Morning to avoid sleep disruption
Morning preferred
Half-life
~9 days (very long)
Hours (estimated)
Reconstitution
—
Saline or bacteriostatic water
04Side Effects & Safety
Parameter
Tesofensine
Thymalin
Insomnia
Dose-related; mitigate with morning timing
—
Dry mouth
Common
—
Nausea
Common
—
Mood changes
Anxiety / agitation possible
—
Cardiovascular events
Phase 3 trial monitoring; not yet FDA-cleared
—
Pregnancy / OB
Contraindicated
Avoid
Injection site reaction
—
Mild erythema at IM site
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Absolute Contraindications
Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
Tesofensine
Thymalin
1. Form
Oral capsule (investigational; not commercial).
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Administration
Swallow whole with water, morning only.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
Morning to mitigate insomnia. Do not dose evening.
Morning preferred during cycle.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Caveat
Monitor BP + HR + mood. Avoid stimulants + MAOIs.
23–25G, 25–38 mm IM needle.
06Stack Synergy
Tesofensine
— no documented stacks
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation